WO2002094283A3 - Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs - Google Patents

Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs Download PDF

Info

Publication number
WO2002094283A3
WO2002094283A3 PCT/GB2002/002196 GB0202196W WO02094283A3 WO 2002094283 A3 WO2002094283 A3 WO 2002094283A3 GB 0202196 W GB0202196 W GB 0202196W WO 02094283 A3 WO02094283 A3 WO 02094283A3
Authority
WO
WIPO (PCT)
Prior art keywords
copd
treatment
cystic fibrosis
lung disease
phospholipids
Prior art date
Application number
PCT/GB2002/002196
Other languages
French (fr)
Other versions
WO2002094283A2 (en
Inventor
Brian Andrew Hills
Derek Woodcock
John Staniforth
Joy Conway
Jim Thompson
Original Assignee
Britannia Pharmaceuticals Ltd
Brian Andrew Hills
Derek Woodcock
John Staniforth
Joy Conway
Jim Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0112326A external-priority patent/GB0112326D0/en
Priority claimed from GB0112330A external-priority patent/GB0112330D0/en
Application filed by Britannia Pharmaceuticals Ltd, Brian Andrew Hills, Derek Woodcock, John Staniforth, Joy Conway, Jim Thompson filed Critical Britannia Pharmaceuticals Ltd
Priority to AU2002255181A priority Critical patent/AU2002255181A1/en
Publication of WO2002094283A2 publication Critical patent/WO2002094283A2/en
Publication of WO2002094283A3 publication Critical patent/WO2002094283A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Surface active phospholipid (SAPL) is administered as a dry powder for the treatment of neutrophil-induced or irreversible degenerative lung disease, especially chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). The SAPL powder is also used in combination therapy to enhance the delivery of biologically active substances to airways to treat COPD and CF, and to enhance the delivery of other actives via mucosal membranes.
PCT/GB2002/002196 2001-05-21 2002-05-21 Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs WO2002094283A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002255181A AU2002255181A1 (en) 2001-05-21 2002-05-21 Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0112330.6 2001-05-21
GB0112326.4 2001-05-21
GB0112326A GB0112326D0 (en) 2001-05-21 2001-05-21 Drug delivery system
GB0112330A GB0112330D0 (en) 2001-05-21 2001-05-21 Treatment of degenerative lung disease

Publications (2)

Publication Number Publication Date
WO2002094283A2 WO2002094283A2 (en) 2002-11-28
WO2002094283A3 true WO2002094283A3 (en) 2003-11-27

Family

ID=26246101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/002196 WO2002094283A2 (en) 2001-05-21 2002-05-21 Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs

Country Status (2)

Country Link
AU (1) AU2002255181A1 (en)
WO (1) WO2002094283A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
FR2889957B1 (en) * 2005-09-01 2008-06-27 Gerard Pieroni USE OF PHOSPHOLIPID DHA FOR THE PREPARATION OF A COMPOSITION FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY.

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003638A1 (en) * 1984-02-23 1985-08-29 Yeda Research And Development Ltd. Compositions containing active lipids
US4937254A (en) * 1985-11-27 1990-06-26 Ethicon, Inc. Method for inhibiting post-surgical adhesion formation by the topical administration of non-steroidal anti-inflammatory drug
WO1991016882A1 (en) * 1990-05-08 1991-11-14 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
CA2117046A1 (en) * 1994-03-04 1995-09-05 Pang N. Shek Liposomal Antibiotic Formulation
US5698537A (en) * 1996-06-18 1997-12-16 Clarion Pharmaceuticals Inc. Method of lowering the viscosity of mucus
WO1999027920A2 (en) * 1997-12-03 1999-06-10 Britannia Pharmaceuticals Limited Use of phospholipids for the manufacture of a medicament for the treatment of asthma
ZA9811553B (en) * 1997-11-22 1999-06-21 Medical Res Council Production of synthetic surfactant
WO1999051244A1 (en) * 1998-04-03 1999-10-14 Britannia Pharmaceuticals Limited Use of phospholipids for the manufacture of a medicament for the prevention of adhesions
WO2000010541A1 (en) * 1998-08-25 2000-03-02 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
WO2000030654A1 (en) * 1998-11-26 2000-06-02 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
WO2001013891A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
WO2001058423A1 (en) * 2000-02-11 2001-08-16 Altana Pharma Ag Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases
WO2002067902A2 (en) * 2001-02-23 2002-09-06 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003638A1 (en) * 1984-02-23 1985-08-29 Yeda Research And Development Ltd. Compositions containing active lipids
US4937254A (en) * 1985-11-27 1990-06-26 Ethicon, Inc. Method for inhibiting post-surgical adhesion formation by the topical administration of non-steroidal anti-inflammatory drug
US4937254B1 (en) * 1985-11-27 1992-08-11 Ethicon Inc
WO1991016882A1 (en) * 1990-05-08 1991-11-14 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
CA2117046A1 (en) * 1994-03-04 1995-09-05 Pang N. Shek Liposomal Antibiotic Formulation
US5698537A (en) * 1996-06-18 1997-12-16 Clarion Pharmaceuticals Inc. Method of lowering the viscosity of mucus
ZA9811553B (en) * 1997-11-22 1999-06-21 Medical Res Council Production of synthetic surfactant
WO1999027920A2 (en) * 1997-12-03 1999-06-10 Britannia Pharmaceuticals Limited Use of phospholipids for the manufacture of a medicament for the treatment of asthma
WO1999051244A1 (en) * 1998-04-03 1999-10-14 Britannia Pharmaceuticals Limited Use of phospholipids for the manufacture of a medicament for the prevention of adhesions
WO2000010541A1 (en) * 1998-08-25 2000-03-02 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
WO2000030654A1 (en) * 1998-11-26 2000-06-02 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
WO2001013891A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
WO2001058423A1 (en) * 2000-02-11 2001-08-16 Altana Pharma Ag Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases
WO2002067902A2 (en) * 2001-02-23 2002-09-06 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANZUETO A ET AL: "EFFECTS OF AEROSOLIZED SURFACTANT IN PATIENTS WITH STABLE CHRONIC BRONCHITIS A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, CHICAGO,IL, US, vol. 278, 5 November 1997 (1997-11-05), pages 1426 - 1431, XP000952889, ISSN: 0098-7484 *
DATABASE WPI Section Ch Week 199947, Derwent World Patents Index; Class B05, AN 1999-562330, XP002231346 *
GRIESE M: "PULMONARY SURFACTANT IN HEALTH AND HUMAN LUNG DISEASES: STATE OF THE ART", EUROPEAN RESPIRATORY JOURNAL, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 13, no. 6, June 1999 (1999-06-01), pages 1455 - 1476, XP000971645, ISSN: 0903-1936 *
WIRTZ H ET AL: "EXOGENOUS SURFACTANT APPLICATION IN RESPIRATORY IN RESPIRATORY FAILURE DUE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE", RESPIRATION, KARGER, BASEL, CH, vol. 62, no. 3, 1995, pages 157 - 159, XP000952901, ISSN: 0025-7931 *

Also Published As

Publication number Publication date
WO2002094283A2 (en) 2002-11-28
AU2002255181A1 (en) 2002-12-03

Similar Documents

Publication Publication Date Title
Gonda The ascent of pulmonary drug delivery
AU2015213681B2 (en) Mast cell stabilizers for lung disease treatment
WO2002024158A3 (en) Pulmonary delivery in treating disorders of the central nervous system
RU2202340C2 (en) Drug delivery system
WO2005025540A3 (en) Mucoactive agents for treating a pulmonary disease
KR19980703876A (en) Powdered pharmaceutical compositions with improved dispersibility
CA2550841A1 (en) Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
CA2359813A1 (en) Nicotine mucosal spray
RU2000131695A (en) DRUG DELIVERY SYSTEM
ATE248583T1 (en) STABILIZED PREPARATIONS USABLE IN DOSAGE INHALERS
KR20050119686A (en) Aerosolization apparatus with capsule puncture alignment guide
WO2002051390A3 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
WO2017011729A1 (en) Combination therapies for the treatment of lung diseases
WO1999027920A3 (en) Use of phospholipids for the manufacture of a medicament for the treatment of asthma
KR930701992A (en) How to get rid of mucus secretions that remain in the lungs of patients
US20230001128A1 (en) Aerosolization systems, methods, and apparatuses
WO1998055104A1 (en) Improvement in medicament administration system
AU2003233921A1 (en) Atomizable liposomes and their use for the pulmonary administration of active substances
WO2002094283A3 (en) Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs
WO2002017894A3 (en) Pharmaceutical formulation of salmeterol and fluticasone propionate
Li et al. Innovative pMDI formulations of spray-dried nanoparticles for efficient pulmonary drug delivery
Garcia-Contreras et al. Aerosol treatment of cystic fibrosis
AU1786199A (en) Pharmaceutical preparation for inhalation of an opioid
JP2006511297A5 (en)
GB2368795A (en) Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP